KALA BIO (KALA) to Release Earnings on Thursday

KALA BIO (NASDAQ:KALA) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect KALA BIO to post earnings of ($0.32) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

KALA BIO Stock Down 8.7%

Shares of NASDAQ:KALA opened at $0.21 on Wednesday. KALA BIO has a 52 week low of $0.21 and a 52 week high of $20.60. The company has a 50-day moving average price of $0.42 and a 200 day moving average price of $2.48. The company has a market cap of $193.57 million, a P/E ratio of -0.04 and a beta of -2.37.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of KALA BIO in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.38.

Hedge Funds Weigh In On KALA BIO

Large investors have recently made changes to their positions in the stock. Woodline Partners LP acquired a new stake in shares of KALA BIO in the first quarter valued at about $1,483,000. Jane Street Group LLC acquired a new position in KALA BIO during the fourth quarter worth about $80,000. Virtu Financial LLC acquired a new position in KALA BIO during the fourth quarter worth about $48,000. Geode Capital Management LLC increased its holdings in KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after buying an additional 1,534 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in KALA BIO in the second quarter valued at about $62,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.